HCW Biologics Inc
hcwbiologics.comHCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company focused on developing immunology-based therapeutics. The company has not disclosed commercial revenue from product sales in the available filing excerpts, operating instead on capital raised through equity offerings and warrant exercises. As of the 10-K filed March 31, 2026, HCW Biologics had raised $5.0 million in a May 2025 unit offering and $4.0 million through a November 2025 warrant inducement transaction. The company faced Nasdaq listing compliance challenges related to its equity rule through late 2025, regaining full compliance as confirmed by the Nasdaq Hearings Panel on February 26, 2026. Founder Hing C. Wong, Ph.D. serves as Chief Executive Officer. The company carried $13.5 million in outstanding legal fees as of December 31, 2024, and entered multiple settlement agreements through 2025 and early 2026 to resolve those obligations. No commercial product revenue, named product pipeline assets, or identified competitors are supported by the available filing excerpts.
Products & Services
No specific pipeline products or commercial products are named in the available filing excerpts.
Revenue Model
The filing excerpts do not disclose commercial product revenue. Capital has been raised through equity unit sales and warrant exercise inducement transactions, including a $5.0 million offering in May 2025 and a $4.0 million warrant exercise transaction in November 2025.
Customers & Markets
The filing excerpts do not identify specific customers or end markets.
Geographic Exposure
The filing references compliance obligations in the United States, the European Union, and other markets, but does not disclose a geographic revenue breakdown.
Financial Snapshot
Loading...
